Intellia Therapeutics’ (NTLA) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a report issued on Tuesday, Benzinga reports. They currently have a $65.00 price objective on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 162.10% from the company’s previous close.

A number of other analysts also recently issued reports on NTLA. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research report on Friday, May 10th. The Goldman Sachs Group lowered Intellia Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $136.00 to $32.00 in a report on Friday, February 23rd. Wedbush reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. Canaccord Genuity Group lifted their target price on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, BMO Capital Markets upped their price target on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $64.75.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $24.80 on Tuesday. The stock has a market capitalization of $2.39 billion, a price-to-earnings ratio of -4.63 and a beta of 1.84. The business’s fifty day moving average is $23.61 and its 200-day moving average is $26.59. Intellia Therapeutics has a one year low of $19.37 and a one year high of $46.50.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($1.35) by $0.29. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 45.35%. The business had revenue of $28.94 million for the quarter, compared to analyst estimates of $15.60 million. Research analysts expect that Intellia Therapeutics will post -4.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTLA. Blue Trust Inc. purchased a new stake in shares of Intellia Therapeutics during the 4th quarter valued at $26,000. Signaturefd LLC lifted its stake in Intellia Therapeutics by 89.3% during the fourth quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock worth $49,000 after purchasing an additional 751 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of Intellia Therapeutics by 35.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock worth $93,000 after purchasing an additional 793 shares in the last quarter. EntryPoint Capital LLC increased its position in shares of Intellia Therapeutics by 61.1% during the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock valued at $113,000 after purchasing an additional 1,563 shares during the last quarter. Finally, Spire Wealth Management raised its holdings in shares of Intellia Therapeutics by 3,789.0% during the 4th quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock valued at $119,000 after buying an additional 3,789 shares in the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.